TABLE II.
Patient characteristics at initiation of nivolumab (n = 225) or cabozantinib (n = 53)
| Characteristic | Pts (n) | Nivolumab [n (%)] | Pts (n) | Cabozantinib [n (%)] | p Value |
|---|---|---|---|---|---|
| Sex (men) | 225 | 179 (80) | 53 | 43 (81) | 0.80 |
|
| |||||
| Age >70 years | 225 | 65 (29) | 53 | 5 (9) | 0.0033 |
|
| |||||
| KPS <80 | 178 | 38 (21) | 48 | 8 (17) | 0.47 |
|
| |||||
| Dx to Tx <1 year | 222 | 107 (48) | 51 | 32 (63) | 0.061 |
|
| |||||
| Prior nephrectomy | 223 | 199 (89) | 52 | 44 (85) | 0.35 |
|
| |||||
| Hypercalcemia | 182 | 15 (8) | 44 | 1 (2) | 0.17 |
|
| |||||
| Anemia | 188 | 144 (77) | 46 | 30 (65) | 0.11 |
|
| |||||
| Neutrophilia | 193 | 13 (7) | 46 | 4 (9) | 0.64 |
|
| |||||
| Thrombocytosis | 194 | 19 (10) | 45 | 3 (7) | 0.51 |
|
| |||||
| Non–clear cell histology | 167 | 26 (16) | 42 | 8 (19) | 0.59 |
|
| |||||
| Sarcomatoid features | 164 | 27 (16) | 43 | 6 (14) | 0.69 |
|
| |||||
| Metastasis | |||||
| >1 Site | 188 | 155 (82) | 48 | 42 (88) | 0.40 |
| To brain | 162 | 10 (6) | 37 | 1 (3) | 0.40 |
| To bone | 179 | 67 (37) | 39 | 14 (36) | 0.86 |
| To liver | 165 | 36 (22) | 37 | 8 (22) | 0.98 |
|
| |||||
| IMDC risk | |||||
| Favourable | 157 | 21 (13) | 39 | 6 (15) | 0.88 |
| Intermediate | 157 | 107 (68) | 39 | 27 (69) | |
| Poor | 157 | 29 (19) | 39 | 6 (15) | |
Pts = patients with relevant data; KPS = Karnofsky performance status; Dx = diagnosis; Tx = treatment; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium.